Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Ginevra Del Giudice (Benevento, Italy), Diana Radicella, Ginevra Del Giudice, Assunta Micco, Mariano Mazza, Mario Del Donno. Effect of pirfenidone on IPF progression. Eur Respir J 2016; 48: Suppl. 60, 2091

Member's Comments

No comment yet.

Related content which might interest you: The effect of pirfenidone on impaired lung function in patients with idiopathic pulmonary fibrosis (IPF) from Czech IPF registry Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Novel lung function tests in patients with interstitial lung disease (ILD) Source: International Congress 2016 – Clinical aspects of ILD Year: 2016 Effect of baseline FVC on lung function decline with nintedanib in patients with IPF Source: International Congress 2015 – Treatment of IPF Year: 2015 Treatment response in hypersensitivity pneumonitis Source: International Congress 2016 – Orphan diseases II Year: 2016 The effect of nintedanib compared to pirfenidone on proliferation of lung fibroblasts from patients with IPF Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 Evaluation of romidepsin (FK228) as a potential therapy for idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – Common mechanisms in lung development and fibrosis Year: 2016 Inhibition of profibrotic signaling in fibroblasts from patients with idiopathic pulmonary fibrosis (IPF) by histone deacetylase-inhibitors (HDACi) or the IPF drug pirfenidone Source: International Congress 2014 – ILDs 1 Year: 2014 Effect of baseline composite physiologic index on benefit of nintedanib in IPF Source: International Congress 2016 – IPF treatment I Year: 2016 Strong reversal of the lung fibrosis disease signature by autotaxin inhibitor GLPG1690 in a mouse model for IPF Source: International Congress 2016 – Therapeutic horizons: novel targets and pharmacological models Year: 2016 Long-term treatment with nintedanib in patients with IPF: An update from INPULSIS®-ON Source: International Congress 2016 – IPF treatment II Year: 2016 Efficacy of pirfenidone in idiopathic pulmonary fibrosis: A single center experience Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Effect of baseline statin use on benefit of nintedanib Source: International Congress 2016 – IPF treatment II Year: 2016 Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013 Annual changes in pulmonary function are independent prognostic factors for the patients with chronic hypersensitivity pneumonia Source: International Congress 2014 – ILDs 3 Year: 2014 Nintedanib prevents IL-1beta-stimulated proliferation of primary human lung fibroblasts from patients with idiopathic pulmonary fibrosis or from control donors Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Long term efficacy of pirfenidone therapy in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – ILDs 3 Year: 2014 Clinical data, lung function and cardiopulmonary exercise testing in CPFE (combined pulmonary fibrosis with emphysema). Results of a cohort of 20 patients Source: International Congress 2014 – ILDs 6 Year: 2014 The role of CCR2+CD4+T cells in lung fibrosis Source: International Congress 2014 – Pathogenetic mechanisms in pulmonary fibrosis Year: 2014 Nintedanib reduces fibrotic markers in the lung in a model of rheumatoid arthritis associated interstitial lung disease Source: International Congress 2016 – ILD pathogenesis Year: 2016 Total lung capacity size matching in fibrosis lung transplantation Source: International Congress 2016 – Long-term outcomes of lung transplantation Year: 2016